Sutro Biopharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
Company: Sutro Biopharma, Inc.
Filing Date: September 3, 2020
Reporting Period: Current Report (Event Date: September 3, 2020)
Context: The Company entered into a material definitive agreement to sublease approximately 115,466 square feet at 111 Oyster Point Boulevard, South San Francisco, California. This space will serve as the Company's new corporate headquarters and research and development facility.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or general liquidity metrics. It specifically details the financial obligations associated with the new sublease agreement:
- Total Estimated Base Rent: Approximately $47.7 million over the lease term (assuming an Initial Premises Commencement Date of April 1, 2021).
- Rent Abatement: Approximately $5.2 million in potential financial benefit provided by the Sublessor for months 7 through 18.
- Security Deposit: Approximately $860,000 (payable in cash or via letter of credit).
- Lease Term: Expires December 31, 2027.
Material Changes
The primary material change is the execution of the sublease agreement with Five Prime Therapeutics, Inc. Key operational changes include:
- Initial Premises: 85,755 square feet with a commencement date expected on or after April 1, 2021, subject to landlord consent and delivery conditions.
- Expansion Premises: 29,711 square feet with a commencement date 24 months following the Initial Premises Commencement Date, subject to acceleration rights.
- Subordination: The sublease is subordinate to the master lease between the Sublessor and HCP Oyster Point III LLC.
Outlook, Risks, and Contingencies
Management Commentary: The Company intends to utilize the premises for corporate headquarters and R&D purposes. The Company retains the right to accelerate commencement dates for both the initial and expansion premises under specific conditions.
Risks and Contingencies:
- Termination Risk: The Sublessor may terminate the Sublease if the master lease with the Landlord is terminated or if the Company fails to remedy a breach of obligations within specified time periods.
- Commencement Uncertainty: The actual start date depends on the Sublessor vacating the premises and obtaining written consent from the Landlord.
- Additional Costs: The Company is responsible for its pro rata share of utilities, operating expenses, and certain taxes and assessments.
Investor Verification Checklist
- Verify the exact date of the Landlord's written consent to determine the actual Initial Premises Commencement Date.
- Confirm the status of the Sublessor's (Five Prime Therapeutics) ability to deliver the premises by the required dates.
- Review the full Sublease agreement (to be filed as an exhibit to the Form 10-Q for the quarter ended September 30, 2020) for specific terms regarding rent abatement conditions and termination clauses.
- Assess the impact of the $47.7 million rent obligation on the Company's future cash flow projections.